Search Results - fibrosis+disorders

3 Results

Sort By:

Treatment of fibrosis-associated pathologies through downstream TGF-β pathway inhibition

Value PropositionInhibits downstream signaling pathway of TGF-β signaling, reducing pleiotropic and off-target effects.Selectively targets tissue specific calpains, increasing efficacy as compared to current TGF-β signaling pathway inhibitory methods.Applicable to several disease models with specific focus on epithelial-to-mesenchymal transition pathologies....

Published: 3/13/2025 | Inventor(s): David Kim, Harry Dietz

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Fibrosis Disorders, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Fibrosis, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Methods and Applications of a Global Assay of Coagulation and Fibrinolysis

Unmet NeedExcessive blood clotting, or thrombotic disorders are a life threatening condition that can cause heart attacks, strokes, organ damage and death. Importantly, those who develop venous thromboembolism (VTE) are at a high risk of recurrence, with a third of patients having a recurrence in 10 years. However, VTEs are often preventable with strategies...

Published: 3/13/2025 | Inventor(s): Neil Goldenberg

Keywords(s): Assay, Blood Disorder, Clinical Diagnostics, Disease Indication, Fibrosis Disorders, In Vitro Diagnostics

Category(s): Technology Classifications > Diagnostics > In Vitro Diagnostics, Clinical and Disease Specializations, Technology Classifications > Research Tools > Assays

Targeted Epigenetic Therapy against Distal Regulatory Element of TGFB2 Expression for Scleroderma and Fibrotic Disease

Unmet NeedScleroderma disorders comprise a heterogeneous group of conditions linked by the presence of thickened, sclerotic skin lesions. These conditions result in a poor quality of life and have a poor prognostic outcome. In particular, systemic sclerosis (SSc) has a 10 year mortality rate of approximately 30%. However, the pathogenic mechanisms of...

Published: 3/13/2025 | Inventor(s): Harry Dietz, Joseph Shin

Keywords(s): Biomarker, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, Fibrosis Disorders, In Vitro Diagnostics, Prognostic Biomarker, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Fibrosis, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Prognostics Biomarkers, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics